Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berzosertib and Irinotecan in Progressive TP53 Mutant Gastric and GEJ Cancer
NCT03641313Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2020
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of berzosertib in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate up to 1 year. Started Nov 2020; status: completed.
02
Drugs
berzosertib
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03641313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03641313.